Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia

Br J Haematol. 2023 Mar;200(6):717-721. doi: 10.1111/bjh.18578. Epub 2022 Nov 28.

Abstract

Data for COVID-19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 patients with ITP, anti-severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate for ITP patients was 91.3%, comparable to that in healthy controls (HCs). However, the antibody titre in ITP patients was significantly lower than that in HCs and declined with ageing. Furthermore, the antibody titre in ITP patients who received a minimum prednisolone dose of at least 5 mg/day at any time-point at or after initial vaccination was lower than that in other patients.

Keywords: COVID-19; SARS-CoV-2; corticosteroids; humoral response; immune thrombocytopenia (ITP); vaccine.

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Purpura, Thrombocytopenic, Idiopathic*
  • RNA, Messenger
  • Thrombocytopenia*
  • Vaccination

Substances

  • COVID-19 Vaccines
  • Antibodies, Viral
  • RNA, Messenger

Associated data

  • UMIN-CTR/UMIN000045267